Trial Profile

Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary)
Indications Interstitial lung diseases; Systemic scleroderma
Focus Adverse reactions
Sponsors Boehringer Ingelheim

Most Recent Events

22 Apr 2024 Status changed from recruiting to active, no longer recruiting.
13 Nov 2023 Planned End Date changed from 31 Mar 2026 to 30 Sep 2026.
13 Nov 2023 Planned primary completion date changed from 31 Dec 2025 to 30 Jun 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com